on Radius Health (NASDAQ:RDUS)
Radius Pharmaceuticals Wins Patent Infringement Case
Radius Pharmaceuticals, a subsidiary of Radius Health, Inc., announced a legal victory in a patent infringement case against Orbicular Pharmaceutical Technologies. The U.S. District Court for the District of Massachusetts ruled in favor of Radius and co-plaintiff Ipsen Pharma S.A.S., upholding the validity of all five patents for TYMLOS® (abaloparatide), a treatment for osteoporosis. The latest of these patents will expire on April 30, 2038.
Radius and Ipsen filed the lawsuit in September 2022, claiming that Orbicular's effort to obtain FDA approval for a generic version of abaloparatide infringed on their patents. This ruling strengthens the position of Radius' patent portfolio and marks a significant win for the company.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Radius Health news